Holen Sie sich die Stockscreener-App
65.87
2.01%
1.30
Vorhandelsmarkt:
66.76
0.89
+1.35%
Schlusskurs vom Vortag:
$64.57
Offen:
$65.35
24-Stunden-Volumen:
1.48M
Relative Volume:
0.87
Marktkapitalisierung:
$7.80B
Einnahmen:
$1.40B
Nettoeinkommen (Verlust:
$316.89M
KGV:
26.43
EPS:
2.4918
Netto-Cashflow:
$644.59M
1W Leistung:
+3.15%
1M Leistung:
+2.14%
6M Leistung:
-3.56%
1J Leistung:
+8.66%
1-Tages-Spanne:
$64.56
$67.35
1-Wochen-Bereich:
$62.38
$67.35
52-Wochen-Spanne:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
65.87 | 7.65B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road (HALO) - Seeking Alpha
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 Guidance - Yahoo Finance
Why Halozyme Shares Are Suddenly Sliding Today - TipRanks
Halozyme director Bernadette Connaughton sells $103,155 in stock - Investing.com
HALOZYME (NASDAQ: HALO) director sells 1,625 shares in Rule 10b5-1 trade - Stock Titan
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 - GlobeNewswire Inc.
Halozyme appoints Darren Snellgrove as CFO - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - MSN
The Bull Case For Halozyme Therapeutics (HALO) Could Change Following Ex-J&J CFO Hire – Learn Why - simplywall.st
Vanguard Group Inc. Sells 62,890 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Holdings Increased by Hussman Strategic Advisors Inc. - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Halozyme (HALO) Rated Buy on Strong Royalty Growth - Insider Monkey
How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFO - Yahoo Finance
How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution Risk - Yahoo Finance
Halozyme Names New CFO As Valuation Gap And Risks Draw Attention - Sahm
[144] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
Halozyme appoints J&J veteran as finance chief - The Pharma Letter
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
MSN Money - MSN
Halozyme Appoints Darren Snellgrove As Chief Financial Officer >HALO - Moomoo
Halozyme to Report First Quarter 2026 Financial and Operating Results - The Malaysian Reserve
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Market Comparisons - Markets Mojo
Halozyme sets May 11 earnings release, call after market close - Stock Titan
Darren Snellgrove Joins Halozyme as CFO, Formerly at Johnson & J - GuruFocus
Halozyme Names Darren Snellgrove Chief Financial Officer to Lead Financial Strategy and Capital Allocation - citybiz
Halozyme Therapeutics Appoints Darren Snellgrove as Chief Financial Officer in April 2026 - Minichart
Vanguard holds 6.17M Halozyme shares (5.21%) (NASDAQ: HALO) - Stock Titan
Halozyme Appoints Darren Snellgrove as Chief Financial Officer - Contract Pharma
Halozyme Appoints New Chief Financial Officer to Drive Growth - TipRanks
Halozyme Therapeutics Names Darren Snellgrove Chief Financial Officer - Moomoo
New Halozyme (NASDAQ: HALO) CFO lands $7.2M equity and cash package - Stock Titan
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $95 - Moomoo
Halozyme Therapeutics Inc Stock Baskets | HAM:RV7 - GuruFocus
HALO Maintained by HC Wainwright & Co. -- Price Target Raised to $95 - GuruFocus
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
Halozyme Therapeutics (NASDAQ:HALO) Given New $95.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Halozyme stock price target to $95 By Investing.com - Investing.com Canada
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Halozyme Therapeutics (HALO) Expected to Announce Earnings on Tuesday - MarketBeat
Halozyme raises outlook, buys Surf Bio - MSN
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 30% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics Inc (HAM:RV7) Stock Price & 30 Year Financial Data - GuruFocus
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):